Efficacy and safety of combination therapy of natural human interferon beta and ribavirin in chronic hepatitis C patients

Internal Medicine

Volumn 50, Issue 19, 2011, Pages 2083-2088

  Arase, Yasuji ^a   Suzuki, Yoshiyuki ^a   Suzuki, Fumitaka ^a   Matsumoto, Naoki ^a   Akuta, Norio ^a   Imai, Norihiro ^a   Seko, Yuya ^a   Sezaki, Hitomi ^a   Kawamura, Yusuke ^a   Kobayashi, Masahiro ^a   Hosaka, Tetsuya ^a   Saito, Satoshi ^a   Ikeda, Kenji ^a   Kobayashi, Mariko ^a   Kumada, Hiromitsu ^a  

^a TORANOMON HOSPITAL   (Japan)

Author keywords

Chronic hepatitis C; Depression; HCV genotype 1b; Natural interferon beta; Ribavirin

Indexed keywords

ALPHA INTERFERON; BETA INTERFERON; RIBAVIRIN; VIRUS RNA;

ADULT; ARTICLE; BECK DEPRESSION INVENTORY; CLINICAL ARTICLE; CLINICAL TRIAL; COHORT ANALYSIS; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DEPRESSION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; GENOTYPE; HAMILTON SCALE; HEMOGLOBIN BLOOD LEVEL; HEPATITIS C; HUMAN; IL28B GENE; LEUKOCYTE COUNT; MALE; PROSPECTIVE STUDY; PROTEINURIA; SIDE EFFECT; SUSTAINED VIROLOGICAL RESPONSE; VIRUS GENE; VIRUS LOAD;

AGED; ANTIVIRAL AGENTS; COHORT STUDIES; DEPRESSION; DRUG THERAPY, COMBINATION; FEMALE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; INTERFERON-BETA; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RIBAVIRIN; RNA, VIRAL; TREATMENT OUTCOME;

EID: 80053474680     PISSN: 09182918     EISSN: 13497235     Source Type: Journal    
DOI: 10.2169/internalmedicine.50.5767     Document Type: Article

References (27)

1. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 358: 958-965, 2001.
2. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 347: 975-982, 2002.
3. McHutchison JG, Manns M, Patel K, et al; International Hepatitis Interventional Therapy Group. Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. Gastroenterology 123: 1061-1069, 2002.
4. Hadziyannis SJ, Sette H, Morgan TR, et al; PEGASYS International Study Group. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 140: 346-355, 2004.
5. Shiffman ML, Ghany MG, Morgan TR, et al. Impact of reducing peginterferon alfa-2a and ribavirin dose during retreatment in patients with chronic hepatitis C. Gastroenterology 132: 103-112, 2007.
6. Iwasaki Y, Ikeda H, Araki Y, et al. Limitation of combination therapy of interferon and ribavirin for older patients with chronic hepatitis C. Hepatology 43: 54-63, 2006.
7. Arase Y, Suzuki F, Suzuki Y, et al. Side effects of combination therapy of peginterferon and ribavirin for chronic hepatitis-C. Intern Med 46: 1827-1832, 2007.
8. Festi D, Sandri L, Mazzella G, et al. Safety of interferon beta treatment for chronic HCV hepatitis. World J Gastroenterol 10: 12-16, 2004.
9. Katamura Y, Suzuki F, Akuta N, et al. Natural human interferon beta plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus and a high viral load. Intern Med 47: 1827-1834, 2008.
10. Arase Y, Suzuki F, Suzuki Y, et al. The efficacy of interferon-beta monotherapy for elderly patients with type C hepatitis of genotype 2. Intern Med 48: 1337-1342, 2009.
11. Kainuma M, Ogata N, Kogure T, et al. The efficacy of a herbal medicine (Mao-to) in combination with intravenous natural interferon-beta for patients with chronic hepatitis C, genotype 1b and high viral load: a pilot study. Phytomedicine 9: 365-372, 2002.
12. Kurosaki M, Enomoto N, Murakami T, et al. Analysis of genotypes and amino acid residues 2209 to 2248 of the NS5A region of hepatitis C virus in relation to the response to interferon-beta therapy. Hepatology 25: 750-753, 1997.
13. Enomoto M, Tamori A, Kawada N, et al. Interferon-beta plus ribavirin for patients with hepatitis C virus genotype 1: a randomized pilot trial. Gut 55: 139-140, 2006.
14. Arase Y, Suzuki F, Akuta N, et al. Efficacy and safety of combination therapy of natural human interferon beta and ribavirin in chronic hepatitis C patients with genotype 1b and high virus load. Intern Med 49: 957-963, 2010.
15. Arase Y, Suzuki F, Akuta N, et al. Efficacy and safety of combination therapy of natural human interferon Beta and ribavirin in chronic hepatitis C patients with genotype 2 and high virus load. Intern Med 49: 965-970, 2010.
16. Beck AT. Comparison of Beck Depression Inventories-IA and-II in psychiatric outpatients. J Pers Assess 67: 588-597, 1996.
17. Hamilton M. A rating scale for depression. J Nerol Neurosurg Psychiat 23: 56-62, 1960.
18. Doglio A, Laffont C, Caroli-Bosc FX, Rochet P, Lefebre J. Second generation of the automated Cobas Amplicor HCV assay improves sensitivity of hepatitis C virus RNA detection and yields results that are more clinically relevant. J Clin Microbiol 37: 1567-1569, 1999.
19. Albadalejo J, Alonso R, Antinozzi R, et al. Multicenter evaluation of the COBAS AMPLICOR HCV assay, an integrated PCR system for rapid detection of hepatitis C virus RNA in the diagnostic laboratory. J Clin Microbiol 36: 862-865, 1998.
20. Dusheiko G, Schmilovitz-Weiss H, Brown D, et al. Hepatitis C virus genotypes: an investigation of type-specific differences in geographic origin and disease. Hepatology 19: 13-18, 1994.
21. Akuta N, Suzuki F, Sezaki H, et al. Association of amino acid substitution pattern in core protein of hepatitis C virusgenotype1b high viral load and non-virological response to interferon-ribavirin combination therapy. Intervirology 48: 372-380, 2005.
22. Ge D, Fellay J, Thompson AJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 461: 399-401, 2009.
23. Tanaka Y, Nishida N, Sugiyama M, et al. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet 41: 1105-1109, 2009.
24. Suppiah V, Moldovan M, Ahlenstiel G, et al. IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet 41: 1100-1104, 2009.
25. Thomas DL, Thio CL, Martin MP, et al. Genetic variation in IL28 B and spontaneous clearance of hepatitis C virus. Nature 461: 798-801, 2009.
26. Rauch A, Kutalik Z, Descombes P, et al; Swiss Hepatitis C Cohort Study; Swiss HIV Cohort Study. Swiss Hepatitis C and HIV Cohort Studies. Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure a genome-wide association study. Gastroenterology 138: 1338-1345, 2010.
27. Kearns NP, Cruickshank CA, McGuigan KJ. A comparison of depression rating scales. Br J Psychiatry 141: 5-49, 1982.